[Preventive treatment of recurrent essential cystitis in women. Comparative study of pipemidic acid and placebo in a daily dose of 200 mg. for 6 months].
Seventy female patients presenting with frequent (less than or equal to 4 episodes per year) recurrent essential cystitis participated in a comparative, double-blind placebo-controlled study of prophylactic treatment with Pipram. Treatment was administered at the dose of 200 mg in the evening at bedtime for 6 months, followed by a post-treatment phase of 6 months. Four episodes of cystitis occurred during the first 6 months in the Pipram group and 11 in the placebo group; a single episode of infection was observed in the placebo group over the entire observation period (1/2 year). The difference between the two groups, Pipram and placebo, was statistically significant at 6 months and at 1 year. The relative risk of infection in the placebo group was 3.02 at 6 months and 3.56 at 12 months. The bacteria responsible for reinfection during and after treatment were resistant to pipemidic acid in 2 out of 2 cases in the Pipram group and in 2 out of 7 cases in the placebo group. Treatment was well tolerated: 2 discontinuations of treatment because of benign side effects in the Pipram group.
D000328:Adult; D000368:Aged; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010876:Pipemidic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence
D009539:Nicotinic Acids; D010876:Pipemidic Acid
Traitement préventif de la cystite essentielle récidivante de la femme. Etude comparative de l'acide pipémidique contre placebo en prise quotidienne de 200 mg pendant 6 mois.